ADHD drug developer Cingulate's Q4 net loss misses analyst expectations as G&A costs rise

Cingulate

18/03/2026 12:10

Overview

US biopharma firm's Q4 net loss widened and missed analyst expectations

R&D expenses fell while G&A costs rose due to pre-commercialization activities

Company closed $12 mln PIPE financing and advanced lead ADHD drug candidate to FDA review in February

Outlook

Company expects current cash to cover capital needs into late fourth qtr 2026

Result Drivers

HIGHER G&A COSTS - Co said increased general and administrative expenses, mainly from pre-commercialization activities, personnel, and legal fees, drove higher net loss

LOWER R&D EXPENSES - Co said research and development expenses fell in Q4 due to decreased clinical operations costs

Company press release: ID:nGNX90Dvd4

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
Miss
-$6.30 mln
-$4.52 mln (5 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cingulate Inc is $25.50, about 118.7% above its March 17 closing price of $11.66

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)